ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), which lacks expression of ER, PR, and HER2, is unique in its pattern of rapid growth and high recurrence risk with associated rapid decline, conferring a poorer prognosis than other subtypes of breast cancer with a median overall survival of less than 2 years [91,92,93].